Alogliptin - Wikipedia, the free encyclopedia
Alogliptin (codenamed SYR-322) is an investigational anti-diabetic drug in the DPP-4 inhibitor class, [1] being developed by Takeda Pharmaceutical Company.
Dipeptidyl peptidase-4 inhibitor - Wikipedia, the free encyclopedia
... more importantly increase insulin secretion and decrease gastric emptying. Drugs belonging to this class are vildagliptin [5], sitagliptin [6], saxagliptin, linagliptin and alogliptin.
Actos-Alogliptin Combination Filing Seeks FDA Approval
Takeda submitted an NDA for a Type 2 diabetes medication that combines the blockbuster thiazolidinedione drug Actos (pioglitazone HCl) with alogliptin, which is in the same drug ...
Alogliptin delayed at least two years
The makers of alogliptin say it will be two years before they have the cardiovascular data needed by the FDA, while the EASD raises concerns over a possible cancer risk with ...
New Drug Application For Alogliptin (syr-322) In The US Submitted By ...
Takeda Pharmaceutical Company Limited (Takeda) has announced that Takeda Global Research & Development Center, Inc. submitted a New Drug Application (NDA) to the United States Food ...
SYR-322 New Drug Application
Alogliptin is a new drug in development for the treatment of Type 2 Diabetes. Alogliptin information includes news, clinical trial results and side effects.
Takeda delays EU registration filings for alogliptin
C o mpany Analysis Drug development strategies of the key players in Pharmaceutical R&D.. T herapy Analysis A therapeutic insight into R&D trends in the pharmaceutical industry..
FDA delays review of Takeda's alogliptin - FierceBiotech
The FDA informed Takeda that it will miss the review deadline for alogliptin, a type 2 diabetes treatment. The NDA was supposed to be reivewed by October 7, 2008. The good news for ...
File:Alogliptin.svg - Wikimedia Commons
Date/Time Thumbnail Dimensions User Comment; current: 01:11, 10 March 2009: 608×547 (2 KB) Fvasconcellos (Talk | contribs) (fixed double bond) 00:28, 10 January 2008
Alogliptin for type 2 diabetes shows promise in early trial
Alogliptin, a highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes, demonstrated efficacy in reducing glucose levels ...
Glucagon.com
Alogliptin is a potent highly selective DPP-4 inhibitor originally discovered by Syrrx (Takeda San Diego) that has completed Phase 3 clinical trials for the treatment of T2DM.
Pharmaceutical Product Development - FDA to Continue Review of ...
FDA to Continue Review of Alogliptin NDA. WILMINGTON, N.C. (October 10, 2008) - PPD, Inc. (Nasdaq: PPDI) today announced that Takeda Pharmaceutical Company Limited reported that ...
ADA: New Drug Alogliptin Controls Glucose Without Risk of Hypoglycemia
An investigational new agent, a highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor, has shown good efficacy and safety in the treatment of type 2 diabetes mellitus ...
Takeda says alogliptin oral diabetes drug effective - Forbes.com
LONDON (Thomson Financial) - Takeda Pharmaceutical Co Ltd has announced at a top diabetes congress that its alogliptin drug can control blood sugar levels effectively alone, and in ...
